Last updated on December 2019

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO]


Brief description of study

Patients with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized to selinexor or placebo until disease progression.

Clinical Study Identifier: NCT03555422

Find a site near you

Start Over